Atrium Therapeutics (RNA) Q1 2026 Earnings
RNA·Reported May 14, 2026·Before market open
Atrium Therapeutics reported Q1 2026 revenue of $19.6M, beat analyst consensus of $2.0M by $17.6M. Diluted EPS came in at $-0.97, beat the $-1.05 consensus by $0.08.
Revenue
$19.6Mbeat by $17.6M
Consensus: $2.0MDiluted EPS
$-0.97beat by $0.08
Consensus: $-1.05
SEC Filings
Earnings release8-K not filed yet
Quarterly report10-Q / 10-K not filed yet
Filings will appear here once submitted to SEC EDGAR.
Q1 2026 Earnings FAQ
Common questions about Atrium Therapeutics 's Q1 2026 earnings report.
Atrium Therapeutics (RNA) reported Q1 2026 earnings on May 14, 2026 before market open.
Atrium Therapeutics reported revenue of $19.6M and diluted EPS of $-0.97 for Q1 2026.
Revenue beat the consensus estimate of $2.0M by $17.6M. EPS beat the consensus estimate of $-1.05 by $0.08.